Cargando…

FRI313 Clinical Implications Due To Long-term Delayed Diagnosis Of Macroprolactinemia

Disclosure: M. Antony: None. S. Gundlapally: None. M. Joglekar: None. B.N. Fritz: None. S. Patel: None. V. Verma: None. R. Kant: None. INTRODUCTION: The most common form of PRL (prolactin) in serum is known as monomeric prolactin and weighs 23kDa (kilo dalton) in size. However, prolactin can bind to...

Descripción completa

Detalles Bibliográficos
Autores principales: Antony, Mc Anto, Gundlapally, Sindhusha, Joglekar, Mansi, Fritz, Brittany Nicole, Patel, Siddharth, Verma, Vipin, Kant, Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553860/
http://dx.doi.org/10.1210/jendso/bvad114.1248
_version_ 1785116274310774784
author Antony, Mc Anto
Gundlapally, Sindhusha
Joglekar, Mansi
Fritz, Brittany Nicole
Patel, Siddharth
Verma, Vipin
Kant, Ravi
author_facet Antony, Mc Anto
Gundlapally, Sindhusha
Joglekar, Mansi
Fritz, Brittany Nicole
Patel, Siddharth
Verma, Vipin
Kant, Ravi
author_sort Antony, Mc Anto
collection PubMed
description Disclosure: M. Antony: None. S. Gundlapally: None. M. Joglekar: None. B.N. Fritz: None. S. Patel: None. V. Verma: None. R. Kant: None. INTRODUCTION: The most common form of PRL (prolactin) in serum is known as monomeric prolactin and weighs 23kDa (kilo dalton) in size. However, prolactin can bind to IgG (immunoglobulin G) to weigh between 150 to 170 kDa. This form of prolactin is biologically inactive and is known as Macroprolactin. Studies have shown that Macroprolactin is responsible for 15 to 46% of cases of hyperprolactinemia. If it is not considered early during the work-up of persistent and asymptomatic hyperprolactinemia, it can lead to prolonged unnecessary work-up and/or treatment. We present a case of macroprolactinemia that was missed for many years leading to significant financial and psychological impact on the patient. CLINICAL CASE: 74-year-old Caucasian male was referred to our endocrinology clinic for further evaluation of chronic hyperprolactinemia. The first documented elevated serum PRL was 90 ng/ml (<20 ng/ml) in 1990.Patient did not recall the reason for checking PRL but recalled having no hypogonadal symptoms or headaches or visual changes. Repeat PRL was normal, and it stayed in range until 2007 when it was reported to be “high”. Other labs revealed normal TSH 1.93 uIU/ml (0.4-4.5 uIU/ml), normal total testosterone 532 ng/dl (264-916 ng/dl). MRI Brain with and without contrast in June 2007 was normal, and patient remained asymptomatic. Repeat PRL was normal, and it stayed in range until 2012 when it was elevated at 95 ng/ml with TSH 2.37 uIU/ml and total testosterone 554 ng/dl. MRI Brain in December 2012 was normal, and patient remained asymptomatic. Repeat PRL however continued to stay elevated since 2012 and ranged between 63.1 to 82.9 ng/ml. The TSH and total testosterone levels have stayed within the normal range. Patient was initially seen at our clinic in August 2022 and was clinically asymptomatic. He expressed a lot of frustration over the chronic diagnostic dilemma and was extremely worried if he indeed had a pituitary tumor that was previously missed on MRI. Pertinent lab results revealed normal ACTH 26.9 (7.2-63.3 pg/ml), low cortisol 4 mcg/dl (6-18 mcg/dl), normal IGF-1 135 (53-222 ng/ml), normal TSH 2.6 uIU/ml, normal Free T4 0.85 (0.8-1.8 ng/dl), elevated total serum PRL 36.8 ng/ml with normal monomeric PRL of 11.7 (4.04-15.2 ng/ml) and elevated macroprolactin percentage of 68%. Patient is currently being treated with hydrocortisone for secondary AI due to chronic prednisone use. CONCLUSION: Testing for Macroprolactin should be considered early in the workup of patients with persistent and asymptomatic hyperprolactinemia. This will not only help to avoid unnecessary testing and costs but will protect the psychological and emotional well-being of the patient. Our case serves as a good example of the benefit that could have been derived from early testing for macroprolactinemia. Presentation: Friday, June 16, 2023
format Online
Article
Text
id pubmed-10553860
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105538602023-10-06 FRI313 Clinical Implications Due To Long-term Delayed Diagnosis Of Macroprolactinemia Antony, Mc Anto Gundlapally, Sindhusha Joglekar, Mansi Fritz, Brittany Nicole Patel, Siddharth Verma, Vipin Kant, Ravi J Endocr Soc Neuroendocrinology & Pituitary Disclosure: M. Antony: None. S. Gundlapally: None. M. Joglekar: None. B.N. Fritz: None. S. Patel: None. V. Verma: None. R. Kant: None. INTRODUCTION: The most common form of PRL (prolactin) in serum is known as monomeric prolactin and weighs 23kDa (kilo dalton) in size. However, prolactin can bind to IgG (immunoglobulin G) to weigh between 150 to 170 kDa. This form of prolactin is biologically inactive and is known as Macroprolactin. Studies have shown that Macroprolactin is responsible for 15 to 46% of cases of hyperprolactinemia. If it is not considered early during the work-up of persistent and asymptomatic hyperprolactinemia, it can lead to prolonged unnecessary work-up and/or treatment. We present a case of macroprolactinemia that was missed for many years leading to significant financial and psychological impact on the patient. CLINICAL CASE: 74-year-old Caucasian male was referred to our endocrinology clinic for further evaluation of chronic hyperprolactinemia. The first documented elevated serum PRL was 90 ng/ml (<20 ng/ml) in 1990.Patient did not recall the reason for checking PRL but recalled having no hypogonadal symptoms or headaches or visual changes. Repeat PRL was normal, and it stayed in range until 2007 when it was reported to be “high”. Other labs revealed normal TSH 1.93 uIU/ml (0.4-4.5 uIU/ml), normal total testosterone 532 ng/dl (264-916 ng/dl). MRI Brain with and without contrast in June 2007 was normal, and patient remained asymptomatic. Repeat PRL was normal, and it stayed in range until 2012 when it was elevated at 95 ng/ml with TSH 2.37 uIU/ml and total testosterone 554 ng/dl. MRI Brain in December 2012 was normal, and patient remained asymptomatic. Repeat PRL however continued to stay elevated since 2012 and ranged between 63.1 to 82.9 ng/ml. The TSH and total testosterone levels have stayed within the normal range. Patient was initially seen at our clinic in August 2022 and was clinically asymptomatic. He expressed a lot of frustration over the chronic diagnostic dilemma and was extremely worried if he indeed had a pituitary tumor that was previously missed on MRI. Pertinent lab results revealed normal ACTH 26.9 (7.2-63.3 pg/ml), low cortisol 4 mcg/dl (6-18 mcg/dl), normal IGF-1 135 (53-222 ng/ml), normal TSH 2.6 uIU/ml, normal Free T4 0.85 (0.8-1.8 ng/dl), elevated total serum PRL 36.8 ng/ml with normal monomeric PRL of 11.7 (4.04-15.2 ng/ml) and elevated macroprolactin percentage of 68%. Patient is currently being treated with hydrocortisone for secondary AI due to chronic prednisone use. CONCLUSION: Testing for Macroprolactin should be considered early in the workup of patients with persistent and asymptomatic hyperprolactinemia. This will not only help to avoid unnecessary testing and costs but will protect the psychological and emotional well-being of the patient. Our case serves as a good example of the benefit that could have been derived from early testing for macroprolactinemia. Presentation: Friday, June 16, 2023 Oxford University Press 2023-10-05 /pmc/articles/PMC10553860/ http://dx.doi.org/10.1210/jendso/bvad114.1248 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Neuroendocrinology & Pituitary
Antony, Mc Anto
Gundlapally, Sindhusha
Joglekar, Mansi
Fritz, Brittany Nicole
Patel, Siddharth
Verma, Vipin
Kant, Ravi
FRI313 Clinical Implications Due To Long-term Delayed Diagnosis Of Macroprolactinemia
title FRI313 Clinical Implications Due To Long-term Delayed Diagnosis Of Macroprolactinemia
title_full FRI313 Clinical Implications Due To Long-term Delayed Diagnosis Of Macroprolactinemia
title_fullStr FRI313 Clinical Implications Due To Long-term Delayed Diagnosis Of Macroprolactinemia
title_full_unstemmed FRI313 Clinical Implications Due To Long-term Delayed Diagnosis Of Macroprolactinemia
title_short FRI313 Clinical Implications Due To Long-term Delayed Diagnosis Of Macroprolactinemia
title_sort fri313 clinical implications due to long-term delayed diagnosis of macroprolactinemia
topic Neuroendocrinology & Pituitary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553860/
http://dx.doi.org/10.1210/jendso/bvad114.1248
work_keys_str_mv AT antonymcanto fri313clinicalimplicationsduetolongtermdelayeddiagnosisofmacroprolactinemia
AT gundlapallysindhusha fri313clinicalimplicationsduetolongtermdelayeddiagnosisofmacroprolactinemia
AT joglekarmansi fri313clinicalimplicationsduetolongtermdelayeddiagnosisofmacroprolactinemia
AT fritzbrittanynicole fri313clinicalimplicationsduetolongtermdelayeddiagnosisofmacroprolactinemia
AT patelsiddharth fri313clinicalimplicationsduetolongtermdelayeddiagnosisofmacroprolactinemia
AT vermavipin fri313clinicalimplicationsduetolongtermdelayeddiagnosisofmacroprolactinemia
AT kantravi fri313clinicalimplicationsduetolongtermdelayeddiagnosisofmacroprolactinemia